Last updated on August 15th, 2026 at 07:03 am
Quick overview: A SAFE looks like a two-page formality. It behaves like a long-term ownership decision. This guide covers exactly what a SAFE note review checks, the valuation cap divide that has opened up between AI and non-AI startups this year, why India requires an entirely different instrument than the US template, and what a professional review actually looks like. For the fuller comparison of SAFEs against convertible notes, our guides on SAFE notes and early-stage funding instruments and SAFE agreement versus convertible note, with real conversion math go deeper on the mechanics.
What is a SAFE note review?
A SAFE note review is exactly what it sounds like: before you sign a Simple Agreement for Future Equity, a lawyer reads the actual document, extracts the terms that determine your future dilution, and explains in plain language what you are agreeing to and what it will do to your ownership once it converts.
The reason this matters more than the document’s length suggests is that a SAFE is short by design. It typically runs a few pages. But those few pages set the valuation cap, the discount, and the conversion mechanics that decide how much of your company an early investor ends up owning once a priced round happens. A two-page document with that much riding on it deserves a genuine read, not a skim.
Why a short document carries such big consequences
Founders often treat a SAFE as a formality because it is standardised, fast to sign, and does not require the extensive negotiation a priced round involves. That standardisation is real and generally a good thing: the Y Combinator template is the market standard, most startup lawyers know it well, and deviating from it without a real reason slows closing and raises questions from investors expecting the standard form.
But standardised does not mean risk-free. The two variables you actually negotiate, the dollar amount and the valuation cap or discount rate, are exactly the two things that determine your future dilution, and getting either one wrong compounds quietly until a priced round makes the consequences visible all at once.
The SAFE terms a review actually checks
Valuation cap. The maximum company valuation at which the SAFE converts into equity. If your SAFE has a $10 million cap and your Series A prices at a $30 million pre-money valuation, the SAFE holder still converts at $10 million, receiving three times as many shares per dollar as your Series A investors do. The cap is the single most consequential number in the document.
Discount rate. An alternative conversion mechanism, typically 15 to 20%, giving the SAFE holder a percentage discount off the price new investors pay in the priced round. Where both a cap and a discount exist, the holder generally gets whichever produces more shares, which is worth modelling rather than assuming.
Pre-money vs post-money structure. Y Combinator moved its standard template to post-money caps in 2018, and post-money is now the clear market standard. Under a post-money cap, your ownership as the SAFE holder is fixed at signing, a $1 million SAFE with a $10 million post-money cap guarantees exactly 10% ownership at conversion, and any additional SAFEs you issue afterward dilute only the founders and existing shareholders, not the earlier SAFE holders. Under the older pre-money structure, every additional SAFE dilutes all the prior ones too, which makes the final ownership picture genuinely unpredictable until the priced round actually closes. Knowing which structure you are signing changes how you should think about issuing further SAFEs before your next round.
MFN (most favoured nation) clause. A provision letting the investor automatically adopt better terms if you issue a more favourable SAFE to someone else later. This sounds harmless in isolation and becomes genuinely complicated once you have stacked several SAFEs with MFN clauses that interact with each other in ways nobody modelled at signing.
Conversion triggers. The specific events that cause the SAFE to convert into equity, most commonly a priced equity round, though some SAFEs include additional triggers worth understanding before you sign.
The AI-versus-non-AI cap divide reshaping 2026 rounds
This is genuinely new context, and it did not exist in this form even two years ago. A real, well-documented two-tier market has opened up in valuation caps depending on whether a startup is categorised as AI or non-AI, and the gap is large enough that using an outdated benchmark to judge whether your own cap is fair can lead you badly astray in either direction.
Data reported by platforms including Carta and AngelList through 2025 and into 2026 shows non-AI pre-seed caps sitting roughly where they were in 2019 and 2020, commonly in the range of six to ten million dollars, with seed caps somewhat higher. AI and machine learning companies, particularly in infrastructure, are commanding caps running two to three times higher at the same stage, often exceeding the peak levels seen during the 2021 funding boom. The concentration of capital into AI specifically has been a real driver: AI and ML companies made up a meaningfully outsized share of total early-stage deals through 2025, which has bid up pricing within the category simply because more capital is chasing the same pool of companies.
The practical implication for a SAFE note review: whether a proposed cap is reasonable now depends on which tier your company actually sits in, not a single blended market average. An AI infrastructure startup being offered a cap that would look aggressive by non-AI standards may be sitting squarely at market rate for its actual category, while a non-AI startup offered a cap benchmarked against AI-tier numbers is being asked to accept meaningfully more dilution than its comparables would justify. Our guide on essential contracts every AI startup must have covers the broader documentation an AI-focused raise typically needs alongside this.
What goes wrong when founders skip the review
The cost of skipping a review is rarely visible at signing. It shows up later, compounded, at the worst possible moment.
The most common failure is stacking. Founders frequently sign several SAFEs with different caps and discounts, never model the cumulative effect, and end up giving away far more than they planned. A common pattern involves a founder expecting minimal dilution because the priced round came in well above all the caps, only for a cap table analysis to reveal the SAFEs converting into a much larger combined stake than expected.
The second is the low-cap trap. A very low early cap that feels like a vote of confidence from an early investor can convert into an outsized ownership chunk once the priced round arrives, costing the founder far more equity than a fair cap would have.
A pattern we see: a founder raises three small SAFEs over a year to extend runway, each at a different low cap, none modelled against the others. The product does well and a strong Series A term sheet arrives. The founder expects light dilution from the SAFEs. Instead, the combined conversion takes a much larger bite than anticipated, because the stacked caps and an MFN clause interacted in a way nobody calculated at signing. A review before each SAFE would have shown the cumulative picture while there was still time to change it.
These are the same kinds of provisions we cover in the contract clauses that quietly slash a startup’s valuation during due diligence, and they are exactly what a review exists to surface.
Do you really need a lawyer to review your SAFE?
A SAFE does not require legal review to be legally valid, and most startup lawyers already know the standard template well, which keeps review costs modest. Legal review earns its cost specifically where it matters most: understanding your actual long-term dilution across every SAFE you have issued or plan to issue, checking any side letter attached to the SAFE (since side letters often carry the terms that matter most and get the least attention at signing), and confirming your proposed cap is genuinely benchmarked against your actual category, not a blended market average that no longer reflects the AI-versus-non-AI divide described above.
SAFE notes in India: why a US SAFE needs extra review (iSAFE)
In India, a US-style SAFE is not a recognised standalone instrument, so it cannot simply be copied across. Indian founders use an adapted version, the iSAFE, structured as Compulsorily Convertible Preference Shares (CCPS) to stay compliant with Indian company law and foreign exchange rules.
A direct SAFE used in India risks being treated as an unregulated forward contract or an unapproved security, which is why the iSAFE takes the legal form of CCPS instead. Copy-pasting a US SAFE into an Indian round often creates compliance and banking friction later, because the back-end mechanics still have to convert into a recognised instrument and complete the required Companies Act and FEMA filings.
The detail matters. iSAFEs are governed by specific sections of the Companies Act, 2013 and must be reported to the RBI under FEMA rules where foreign investment is involved. For an Indian founder, this means a SAFE note review is not just about cap and discount. It is also about whether the instrument is structured and filed correctly, a layer that US-focused templates simply do not address. If you are weighing the options, our comparison of a SAFE agreement and a convertible note is a useful starting point, and our company registration service can help structure the entity side of a raise correctly from the outset.
What a professional SAFE note review looks like
A good review is more than a read-through. It extracts the key terms, models how the SAFE converts under realistic scenarios, and shows you the dilution in numbers rather than abstractions. It checks any side letter, because side letters often carry the terms that matter most and get the least attention. It benchmarks your proposed cap against current data for your actual category, AI or non-AI, rather than a generic market average.
For Indian rounds, it confirms the instrument is structured and filed correctly under the Companies Act and FEMA, not just commercially sensible. And throughout, it translates the legal language into plain terms, so you understand not only what the SAFE says but what it will actually do to your ownership. That combination, commercial modelling plus compliance plus plain-English explanation, is what separates a real review from a quick glance. Our term sheet negotiation guide and cap table guide cover the fuller picture your SAFE terms feed into once a priced round arrives.
Conclusion
A SAFE note review is a small step that protects one of the most important things you own: your equity. The takeaways worth keeping are simple. First, the SAFE looks simple but behaves like a long-term ownership decision, so the terms deserve real attention. Second, the cap, discount, pre or post-money structure, MFN clause, and triggers are where your dilution is decided, and they are easiest to change before you sign, not after. Third, in 2026 specifically, whether your cap is fair now depends on which category your startup actually sits in, since AI and non-AI companies are being priced on genuinely different scales. Fourth, in India, the instrument also has to be structured and filed correctly, which adds a compliance layer a generic template will miss.
If you have a SAFE in front of you, get it reviewed before you sign rather than after. My Legal Pal’s lawyers review SAFE notes and startup investment documents for founders in India and internationally, model your dilution, and tell you in plain terms what you are agreeing to. You can see how our online contract review for startups works, or visit MyLegalPal.com to have your SAFE reviewed.
Frequently asked questions
Do I really need a lawyer to review my startup’s investment documents?
Not always for legal validity, since a SAFE does not require legal review to be enforceable and most startup lawyers already know the standard template well. Review earns its value specifically in understanding your true long-term dilution across every instrument you’ve issued, checking side letters that carry the terms that matter most, and confirming your cap is genuinely benchmarked against your actual category.
What is the difference between a valuation cap and a discount in a SAFE?
A valuation cap sets the maximum company valuation at which the SAFE converts, protecting the investor if your company’s value grows significantly before the priced round. A discount rate instead gives the investor a percentage reduction off whatever price new investors pay in that round. Where both exist, the investor generally gets whichever produces more shares.
Is a pre-money or post-money SAFE better for founders?
Post-money is now the market standard, and it gives founders more predictability: your ownership dilution from a single SAFE is fixed and calculable at signing, since additional SAFEs dilute only the founders and existing shareholders, not earlier SAFE holders. Under the older pre-money structure, every additional SAFE dilutes all the prior ones too, making the final picture unpredictable until the priced round actually closes.
Are SAFE notes legally recognised in India?
Not in their US form. Indian founders use the iSAFE, structured as Compulsorily Convertible Preference Shares under the Companies Act, 2013, to achieve the same commercial outcome within an instrument Indian company law and FEMA actually recognise. A direct copy of a US SAFE risks being treated as an unregulated instrument.
Does the valuation cap I should expect depend on whether my startup is an AI company?
Increasingly, yes. Data from major startup finance platforms through 2025 and into 2026 shows AI and machine learning startups commanding valuation caps roughly two to three times higher than non-AI startups at the same stage, driven by a disproportionate share of early-stage capital concentrating into the category. Benchmarking your own cap against the right comparable set, not a blended market average, matters more now than it did a few years ago.
How much does a SAFE note review cost?
Costs vary by provider and complexity, but a standard SAFE review is typically modest relative to the amount being raised and the dilution at stake, since most startup lawyers already know the standard template well. Our online contract review services guide covers typical pricing for startup document review generally.
This article is general information, not legal advice. SAFE note terms, market benchmarks, and India’s iSAFE compliance requirements change over time. For advice on your own SAFE, speak to a qualified lawyer before you sign.
Written by Prakhar Rai, founder of My Legal Pal and licensed attorney (LL.B; Master of Business Laws, NLSIU Bangalore). Connect on LinkedIn.
If you have a SAFE note or convertible instrument in front of you, our team can review it before you sign. Speak to our contract lawyers in India or the USA today.
